Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02634307 · ClinicalTrials.gov registry record · Phase 3
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,057
- Enrollment target
NCT02634307 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 1,057 participants.
The verdict
NCT02634307, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,057 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). The secondary objective of this study is to evaluate treatment effect over time in adult participants with RRMS treated with ALKS 8700.
Interventions
- DRUG ALKS 8700
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,057 participants |
| Start Date | 2015-12-10 |
| Est. Completion | 2021-11-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02634307
The ClinicalTrials.gov registry entry for NCT02634307 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,057 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALKS 8700 is the first listed.
NCT02634307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02634307 about?
NCT02634307 is a clinical study titled "A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1". The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). The secondary objective of this study is to evaluate treatment effect over time in adult participants with RRMS treated with ALKS ...
What is the current status of trial NCT02634307?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,057 participants. The study started on 2015-12-10. Estimated completion is 2021-11-11.
What interventions are being tested in trial NCT02634307?
The interventions under investigation include: ALKS 8700 (DRUG).
Who is sponsoring clinical trial NCT02634307?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.